Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;10(12):882-889.
doi: 10.1016/S2213-8587(22)00247-9. Epub 2022 Sep 28.

Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history

Angelo Avogaro  1 , Saula Vigili de Kreutzenberg  2 , Mario Luca Morieri  2 , Gian Paolo Fadini  2 , Stefano Del Prato  3
Affiliations
Review

Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history

Angelo Avogaro et al. Lancet Diabetes Endocrinol. 2022 Dec.

Abstract

The life history theory assumes that all organisms are under selective pressure to harvest external resources and allocate them to maximise fitness: only organisms making the best use of energy obtain the greatest fitness benefits. The trade-off of energy spans four functions: maintenance, growth, reproduction, and defence against pathogens. The innovative antihyperglycaemic agents glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors decrease bodyweight and have the potential to counter low-grade inflammation. These key activities could rewire two components of the life history theory operative in adulthood-ie, maintenance and defence. In this Personal View, we postulate that the benefits of these medications on the cardiovascular system, beyond their glucose-lowering effects, could be mediated by the reduction of the maintenance cost driven by obesity and efforts spent on blunting low-grade inflammation.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AA received research grants, lecture, and advisory board fees from Mundipharma, Merck Sharp & Dome, AstraZeneca, Novartis, Boehringer Ingelheim, Sanofi, Mediolanum, Novo Nordisk, Eli Lilly, Servier, and Takeda. MLM received lecture fees, advisory fees, and grant support from Mylan, SLA Pharma, Servier Laboratories, Eli Lilly, MSD, and Novo Nordisk. GPF received lecture fees, consultancy fees, grant support, and advisory board fees from Abbott, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk, Sanofi, and Takeda. SDP consulted for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, and Sanofi, and received funding for these consulting services; received grant support from AstraZeneca and Boehringer Ingelheim; and received speaker fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, MSD, Novartis, Novo Nordisk, and Sanofi. SVdK declares no competing interests.

MeSH terms

Substances

LinkOut - more resources